<DOC>
	<DOCNO>NCT02045836</DOCNO>
	<brief_summary>The purpose study assess immunogenicity , reactogenicity safety GSK Biologicals HZ/su candidate vaccine first dose co-administered Pneumovax 23™ vaccine adult age 50 year older.The impact HZ/su vaccine Pneumovax 23™ vaccine immune response also evaluate .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Safety Study GSK Biologicals ' Herpes Zoster ( HZ ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ Adults Aged 50 Years Older</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . A male female age 50 year old time first vaccination study vaccine ( ) . Written inform consent obtain subject . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . A prednisone dose &lt; 20 mg/day allow . Inhaled , topical intraarticular corticosteroid allow . Administration plan administration vaccine foreseen study protocol within period start 30 day first dose study vaccine ( ) end 30 day last dose study vaccine . This include type vaccine live , inactivated subunit vaccine . Administration longacting immunemodifying drug within six month prior first vaccine dose expect administration time study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Previous vaccination Varicellazoster virus ( VZV ) HZ and/or plan administration study HZ VZV vaccine study vaccine . History HZ . History document pneumococcal infection within 5 previous year . Prior receipt pneumococcal vaccine plan use vaccine study period , study vaccine . Any confirm suspected immunosuppressive immunodeficient condition result disease immunosuppressive/cytotoxic therapy . History reaction hypersensitivity likely exacerbate component vaccine . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C /99.5°F oral route . The preferred route record temperature study oral . Subjects minor illness ( mild diarrhea , mild upper respiratory infection ) without fever may , enrol discretion investigator . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution 2 month last dose study vaccine . Any person cerebrospinal fluid ( CSF ) leak , cochlear implant , chronic renal failure , nephrotic syndrome , functional anatomic asplenia . Any condition , opinion investigator , prevents subject participate study . Any condition , judgment investigator , would make intramuscular ( IM ) injection unsafe .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pneumovax 23</keyword>
	<keyword>Co-administration</keyword>
	<keyword>Herpes zoster</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Adults</keyword>
</DOC>